BridgeBio heart drug approved by FDA, setting up battle with Pfizer
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...
US FDA approves BridgeBio's drug for rare heart condition
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
BridgeBio Gets US Approval for Heart Drug to Compete with Pfizer
BridgeBio Pharma Inc. gained US approval for a drug to treat a progressive and deadly form of heart disease, paving the way ...
STAT6h
BridgeBio wins FDA approval for heart disease drug
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...
News Medical3d
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis
A new type of therapy that 'edits' a gene in patients with a rare heart condition has been shown to be safe and effective, according to research from UCL and the Royal Free Hospital. Results for the ...
Healthline10d
ATTR Amyloidosis Symptoms, Diagnosis, and Treatments
ATTR amyloidosis results from the buildup of transthyretin in the body. It can be inherited or acquired and can affect your heart, kidneys, and nervous system. While there’s no cure, treatment ...
Transplant doctors help suburban veteran keep special tattoo. Here's what it meant
Louis B. Smith Jr. served in the Army for 21 years. But Smith faced one of his most life-threatening moments off the ...
CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.